Josh D. Epworth, MSN, ARNP
University of Washington Medical Center

Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on maintenance therapy with the oral proteasome inhibitor ixazomib, which significantly prolonged progression-free survival following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (Abstract 301).

Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.